Fourrier François, Dubois Didier, Pronnier Philippe, Herbecq Patrick, Leroy Olivier, Desmettre Thibaut, Pottier-Cau Elodie, Boutigny Hervé, Di Pompéo Christophe, Durocher Alain, Roussel-Delvallez Micheline
Department of Intensive Care, Hôpital Roger Salengro, Université de Lille II, France.
Crit Care Med. 2005 Aug;33(8):1728-35. doi: 10.1097/01.ccm.0000171537.03493.b0.
To document the effect of gingival and dental plaque antiseptic decontamination on the rate of nosocomial bacteremias and respiratory infections acquired in the intensive care unit (ICU).
Prospective, multicenter, double-blind, placebo-controlled efficacy study.
Six ICUs: three in university hospitals and three in general hospitals.
A total of 228 nonedentulous patients requiring endotracheal intubation and mechanical ventilation, with an anticipated length of stay > or =5 days.
Antiseptic decontamination of gingival and dental plaque with a 0.2% chlorhexidine gel or a placebo gel, three times a day, during the entire ICU stay.
Demographic and clinical characteristics, organ function data (Logistic Organ Dysfunction score), severity of condition (Simplified Acute Physiologic Score), and dental plaque status were assessed at baseline and until 28 days. Bacteriologic sampling of dental plaque and saliva was done every 5 days, and blood, tracheal aspirate, and bronchoalveolar lavage cultures were performed when appropriate. The primary efficacy end point was the incidence of bacteremia, bronchitis, and ventilator-associated pneumonia, expressed as a percentage and per 1000 ICU days. All baseline characteristics were similar between the treated and the placebo groups. The incidence of nosocomial infections was 17.5% (13.2 per 1000 ICU days) in the placebo group and 18.4% (13.3 per 1000 ICU days) in the plaque antiseptic decontamination group (not significant). No difference was observed in the incidence of ventilator-associated pneumonia per ventilator or intubation days, mortality, length of stay, and care loads (secondary end points). On day 10, the number of positive dental plaque cultures was significantly lower in the treated group (29% vs. 66%; p < .05). Highly resistant Pseudomonas, Acinetobacter, and Enterobacter species identified in late-onset ventilator-associated pneumonia and previously cultured from dental plaque were not eradicated by the antiseptic decontamination. No side effect was reported.
Gingival and dental plaque antiseptic decontamination significantly decreased the oropharyngeal colonization by aerobic pathogens in ventilated patients. However, its efficacy was insufficient to reduce the incidence of respiratory infections due to multiresistant bacteria.
记录牙龈和牙菌斑抗菌消毒对重症监护病房(ICU)获得性医院菌血症和呼吸道感染发生率的影响。
前瞻性、多中心、双盲、安慰剂对照疗效研究。
六个ICU:三个在大学医院,三个在综合医院。
总共228例需要气管插管和机械通气的无牙患者,预计住院时间≥5天。
在整个ICU住院期间,每天三次用0.2%氯己定凝胶或安慰剂凝胶对牙龈和牙菌斑进行抗菌消毒。
在基线时以及直至28天评估人口统计学和临床特征、器官功能数据(逻辑器官功能障碍评分)、病情严重程度(简化急性生理学评分)和牙菌斑状况。每5天进行一次牙菌斑和唾液的细菌学采样,并在适当的时候进行血液、气管吸出物和支气管肺泡灌洗培养。主要疗效终点是菌血症、支气管炎和呼吸机相关性肺炎的发生率,以百分比和每1000个ICU日表示。治疗组和安慰剂组的所有基线特征相似。安慰剂组医院感染发生率为17.5%(每1000个ICU日13.2例),牙菌斑抗菌消毒组为18.4%(每1000个ICU日13.3例)(无统计学意义)。在每台呼吸机或插管日的呼吸机相关性肺炎发生率、死亡率、住院时间和护理负荷(次要终点)方面未观察到差异。在第10天,治疗组的牙菌斑培养阳性数显著低于安慰剂组(29%对66%;p<0.05)。在迟发性呼吸机相关性肺炎中鉴定出并先前从牙菌斑培养出的高度耐药的假单胞菌属、不动杆菌属和肠杆菌属未被抗菌消毒根除。未报告副作用。
牙龈和牙菌斑抗菌消毒显著降低了通气患者口咽部需氧病原体的定植。然而,其疗效不足以降低多重耐药菌引起的呼吸道感染发生率。